$14.92
9.90% today
Nasdaq, Apr 04, 09:19 pm CET
ISIN
US89422G1076
Symbol
TVTX
Sector
Industry

Travere Therapeutics Inc Stock price

$16.56
-3.24 16.36% 1M
+2.91 21.32% 6M
-0.86 4.94% YTD
+9.58 137.25% 1Y
-12.44 42.90% 3Y
+1.77 11.97% 5Y
-7.29 30.57% 10Y
Nasdaq, Closing price Thu, Apr 03 2025
-1.38 7.69%
ISIN
US89422G1076
Symbol
TVTX
Sector
Industry

Key metrics

Market capitalization $1.47b
Enterprise Value $1.50b
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 6.43
P/S ratio (TTM) P/S ratio 6.30
P/B ratio (TTM) P/B ratio 24.51
Revenue growth (TTM) Revenue growth 17.27%
Revenue (TTM) Revenue $233.18m
EBIT (operating result TTM) EBIT $-256.18m
Free Cash Flow (TTM) Free Cash Flow $-237.48m
Cash position $370.70m
EPS (TTM) EPS $-4.10
P/E forward negative
P/S forward 3.80
EV/Sales forward 3.88
Short interest 13.95%
Show more

Is Travere Therapeutics Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,794 stocks worldwide.

Travere Therapeutics Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

15 Analysts have issued a Travere Therapeutics Inc forecast:

14x Buy
93%
1x Hold
7%

Analyst Opinions

15 Analysts have issued a Travere Therapeutics Inc forecast:

Buy
93%
Hold
7%

Financial data from Travere Therapeutics Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
233 233
17% 17%
100%
- Direct Costs 51 51
14% 14%
22%
182 182
31% 31%
78%
- Selling and Administrative Expenses 177 177
8% 8%
76%
- Research and Development Expense 218 218
10% 10%
93%
-213 -213
28% 28%
-91%
- Depreciation and Amortization 44 44
7% 7%
19%
EBIT (Operating Income) EBIT -256 -256
25% 25%
-110%
Net Profit -322 -322
5% 5%
-138%

In millions USD.

Don't miss a Thing! We will send you all news about Travere Therapeutics Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Travere Therapeutics Inc Stock News

Neutral
Business Wire
4 days ago
SAN DIEGO--(BUSINESS WIRE)---- $TVTX--Travere's late-breaking oral presentation at NKF details partial and complete proteinuria remission data from the DUPLEX Study of FILSPARI in FSGS.
Positive
Investors Business Daily
6 days ago
The stock market is attempting to rebound amid President Donald Trump's trade war. The post Two S&P 500 Giants And Biotech Play Lead Five Stocks To Watch As Market Struggles appeared first on Investor's Business Daily.
Neutral
GlobeNewsWire
18 days ago
sNDA submission based on results from Phase 3 DUPLEX and Phase 2 DUET studies of FILSPARI in FSGS If approved, FILSPARI could become the first and only FDA-approved treatment for FSGS, a rare kidney condition and a leading cause of kidney failure Additionally, the FDA notified the Company that REMS monitoring for embryo-fetal toxicity is no longer necessary; the Company plans to submit an amend...
More Travere Therapeutics Inc News

Company Profile

Travere Therapeutics, Inc. is a biopharmaceutical company. It engages in the identification, development, commercialization, and distribution of therapies to people living with rare diseases. Its products include Chenodal, Cholbam, and Thiola. The company was founded by Martin Shkreli on February 8, 2008 and is headquartered in San Diego, CA.

Head office United States
CEO Eric Dube
Employees 385
Founded 2008
Website www.travere.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today